Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + gemcitabine + cisplatin as first-line therapy for advanced or metastatic urothelial carcinoma
ChiCTR2000035289Phase 2Recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Aug 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in transitional cell carcinoma (TCC), sponsored by Harbin Medical University Cancer Hospital. Primary endpoint: 6-month progression-free survival rate. Started Aug 2020; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on ChiCTR2000035289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035289.